Foresite Capital’s Jim Tananbaum Welcomes Molly He

Recently, Foresite Capital announced Molly He, PhD., as one of their venture partners. This way, the former senior director of Illumina will join the management team at the healthcare growth equity firm. Dr. Molly has over 15 years of experience in the competitive healthcare industry, especially in pharmaceutical and genomic research.

According to Ideamensch, Foresite Capital’s chief executive officer, Jim Tananbaum praised the scientists as a respected researcher and expert in next-generation sequencing. He added that the management of Foresite Capital was thrilled to have Dr. He be part of the leadership team. They are hopeful that she would provide the company with innovative strategies. In addition, Jim recommended Molly’s leadership record noting that such excellence is an invaluable resource for the enterprise. Her inclusion in the company’s leadership team will not only help Foresite Capital to expand its portfolio, but also enhance its growth. Given her past records of accomplishment, the management is optimistic about her contribution to the company.

At Illumina, Dr. He was responsible for global protein reagent innovation and improvements. Her visionary leadership helped the company grow into a leading biotech firm. Before joining Illumina, the scientist worked for Pacific BioSciences as the head of protein sciences. Dr. He has also worked in the pharmaceutical industry for over a decade. In the industry, she worked in firms that focus on structural-based design of antibody. She is also experienced in the development of small molecule drugs targeting immune diseases and cancer.

Dr. He’s professional success is attributed to her outstanding academic background. The researcher holds a degree in biochemistry from Nankai University and a doctorate in protein biophysics from the University of California. Dr. He has more than 20 publications and two dozen patent applications.

About Jim Tananbaum

Jim Tananbaum is the founder of Foresite Capital Management. He founded the healthcare investment company in 2010. Over the years, he has worked hard to bring in other like-minded partners who have played an integral role in the company’s growth. More details can be found on his LinkedIn account.

In addition, Jim has founded other corporations, including Theravance, GelTex, and Prospect Venture Partners. He is an alumnus of both the Harvard Business School and Harvard Medical School. Jim holds a master’s of science degree from the prestigious MIT.

See more:

Leave a Reply

Your email address will not be published. Required fields are marked *